Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma

Publication date: Available online 23 March 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hiroshi Ureshino, Kazuharu Kamachi, Shinya KimuraAbstractMogamulizumab, a defucosylated humanized monoclonal antibody against C–C chemokine receptor 4 (CCR4), has been approved for the treatment of relapsed adult T-cell leukemia/lymphoma (ATL). Compared with conventional chemotherapy, mogamulizumab monotherapy displayed more effecacy in relapsed ATL making mogamulizumab a promising therapeutic agent. However, mogamulizumab could increase graft-versus-host disease, resulting in poor survival outcome in allogenic stem cell transplant (allo-SCT) setting. Perhaps, the efficacy of mogamulizumab could be establisded by the occurrence of skin rashes and/or CCR4 mutational status. Hence, this study reviews, the current treatment strategies for patients with ATL, focuses on the safety and efficacy (single agent and combined with chemotherapy or allo-SCT) of mogamulizumab.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research